Zoetis Inc. (FRA:ZOE)

Market Cap	46.30B -36.8%
Revenue (ttm)	8.01B +2.7%
Net Income	2.26B +9.1%
EPS	5.06 +11.6%
Shares Out	n/a
PE Ratio	20.49
Forward PE	19.00
Dividend	1.76 (1.68%)
Ex-Dividend Date	Jan 20, 2026

Volume	455
Average Volume	251
Open	101.22
Previous Close	101.30
Day's Range	101.20 - 104.92
52-Week Range	99.45 - 170.08
Beta	n/a
RSI	48.23
Earnings Date	Feb 13, 2026

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph...

• Industry: Pharmaceutical Preparations
• Founded: 1950
• Employees: 13,800
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ZOE

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Financial numbers in USD